Bausch Health Companies Inc

BHCNYSE · USD
8.47USD0.00 (+0.60%)
9610

Bausch Health Companies Inc (BHC) Covered Calls

Bausch Health Companies Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 53.57%, average versus the past year. BHC's highest covered call setup is the $13.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 55.69% out of the money with 154 days to expiration, a 56.29% return until expiration, and a 133.41% theoretical annualized return. Across the setups shown, annualized returns run from 59.61% to 133.41% at strikes between $8.50 and $15.00, with 7 to 434 days to expiration, as of Nov 13, 2026.

Read more

Running BHC covered calls helps you generate income from Bausch Health Companies Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BHC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BHC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BHC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BHC covered call is worth writing.

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States.

2027-04-1615413.0055.690.050.30470.0056.29133.41-0.60+0.1410.25
2026-11-2078.501.800.050.1520.002.40124.89-0.60+0.374700.10
2027-01-156310.0019.760.050.25170.0020.36117.95-0.60+0.197,0940.20
2027-04-1615412.0043.710.100.40375.0044.91106.44-1.20+0.1910.30
2026-12-18359.007.780.050.3570.008.3887.43-0.60+0.314360.30
2027-04-1615411.0031.740.200.45285.0034.1380.90-2.40+0.2570.25
2026-11-27148.501.800.100.4025.002.9978.06-1.20+0.4500.30
2027-12-1739915.0079.640.100.55675.0080.8473.95-1.20+0.181,2380.45
2028-01-2143415.0079.640.100.80675.0080.8467.99-1.20+0.221,9200.70
2027-04-1615410.0019.760.450.75210.0025.1559.61-5.39+0.372220.30

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank53.57% Moderate
  • Market cap (M$)3,170
  • 52 weeks high-6.31%
  • 52 weeks low95.61%
  • Analyst recommendationHold
    2.80
  • Target price$8.50
    0.35% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-17
  • P/E—
  • Future P/E1.89
  • EPS (ttm)-2.29
  • EPS growth next 5 years-1.61%

As of Nov 17, 2026